Financials United Therapeutics Corporation

Equities

UTHR

US91307C1027

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2024-06-17 EDT 5-day change 1st Jan Change
297.1 USD +3.12% Intraday chart for United Therapeutics Corporation +7.92% +35.09%

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 3,865 6,746 9,731 12,674 10,333 13,180 - -
Enterprise Value (EV) 1 3,977 5,711 9,637 12,513 8,039 10,991 9,231 7,944
P/E ratio -36.9 x 13.2 x 21.5 x 18.5 x 11.1 x 12.1 x 11.1 x 11 x
Yield - - - - - - - -
Capitalization / Revenue 2.67 x 4.55 x 5.77 x 6.55 x 4.44 x 4.81 x 4.44 x 4.17 x
EV / Revenue 2.74 x 3.85 x 5.72 x 6.46 x 3.45 x 4.02 x 3.11 x 2.52 x
EV / EBITDA -28.1 x 8.87 x 15.9 x 12.1 x 6.49 x 7.71 x 6.22 x 5.33 x
EV / FCF -13.7 x 8.2 x 20.2 x 18.9 x 10.8 x 10.2 x 8.09 x 5.97 x
FCF Yield -7.3% 12.2% 4.95% 5.3% 9.3% 9.76% 12.4% 16.8%
Price to Book 1.39 x 1.99 x 2.67 x 2.67 x 1.73 x 1.92 x 1.64 x 1.44 x
Nbr of stocks (in thousands) 43,881 44,441 45,037 45,577 46,994 44,366 - -
Reference price 2 88.08 151.8 216.1 278.1 219.9 297.1 297.1 297.1
Announcement Date 20-02-26 21-02-24 22-02-24 23-02-22 24-02-21 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 1,449 1,483 1,686 1,936 2,328 2,737 2,965 3,159
EBITDA 1 -141.7 643.5 605.8 1,031 1,238 1,425 1,484 1,490
EBIT 1 -187.6 593.6 555.9 979.7 1,185 1,413 1,553 1,584
Operating Margin -12.95% 40.02% 32.98% 50.6% 50.91% 51.61% 52.37% 50.16%
Earnings before Tax (EBT) 1 -165 638.9 593.9 950.6 1,274 1,538 1,698 1,731
Net income 1 -104.5 514.8 475.8 727.3 984.8 1,187 1,292 1,313
Net margin -7.21% 34.71% 28.23% 37.56% 42.31% 43.35% 43.57% 41.57%
EPS 2 -2.390 11.54 10.06 15.00 19.81 24.49 26.73 26.93
Free Cash Flow 1 -290.3 696.4 477.4 663.7 747.6 1,073 1,141 1,331
FCF margin -20.04% 46.95% 28.32% 34.28% 32.12% 39.2% 38.48% 42.13%
FCF Conversion (EBITDA) - 108.22% 78.8% 64.37% 60.38% 75.31% 76.89% 89.33%
FCF Conversion (Net income) - 135.28% 100.34% 91.26% 75.91% 90.42% 88.3% 101.36%
Dividend per Share 2 - - - - - - - -
Announcement Date 20-02-26 21-02-24 22-02-24 23-02-22 24-02-21 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 415.2 461.9 466.9 516 491.5 506.9 596.5 609.4 614.7 677.7 685.3 702.6 698.1 795.3 840.8
EBITDA 182.4 300.5 214.5 327.2 188.8 297.7 326.3 340.3 273.8 371.3 - - - - -
EBIT 1 169.8 288 201.8 314.3 175.6 284.4 313.4 327 260.1 356.3 365.8 373.6 339.9 502.5 503.9
Operating Margin 40.9% 62.35% 43.22% 60.91% 35.73% 56.11% 52.54% 53.66% 42.31% 52.57% 53.38% 53.18% 48.69% 63.18% 59.93%
Earnings before Tax (EBT) 1 140.5 308.7 150.6 312.5 178.8 291.9 335.2 351.8 295.4 398.6 400.6 409.2 352.7 545.2 547.2
Net income 1 112.2 239.9 116 239.3 132.1 240.9 259.2 267.6 217.1 306.6 310 316.6 281.7 430.7 432.3
Net margin 27.02% 51.94% 24.84% 46.38% 26.88% 47.52% 43.45% 43.91% 35.32% 45.24% 45.24% 45.06% 40.34% 54.16% 51.41%
EPS 2 2.350 5.030 2.410 4.910 2.670 4.860 5.240 5.380 4.360 6.170 6.264 6.525 5.821 9.180 9.210
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 22-02-24 22-05-04 22-08-03 22-11-02 23-02-22 23-05-03 23-08-02 23-11-01 24-02-21 24-05-01 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 112 - - - - - - -
Net Cash position 1 - 1,035 94.8 161 2,294 2,189 3,948 5,235
Leverage (Debt/EBITDA) -0.7876 x - - - - - - -
Free Cash Flow 1 -290 696 477 664 748 1,073 1,141 1,331
ROE (net income / shareholders' equity) -3.75% 16.7% 12.9% 16.6% 18.3% 17.6% 15.7% 13.1%
ROA (Net income/ Total Assets) 15.6% 12.1% 9.85% 13% 14.9% 15.2% 14.3% 12.6%
Assets 1 -671.4 4,264 4,832 5,607 6,606 7,804 9,057 10,444
Book Value Per Share 2 63.40 76.40 81.00 104.0 127.0 154.0 181.0 206.0
Cash Flow per Share 2 -4.720 16.90 12.60 16.50 19.70 25.80 25.60 28.70
Capex 1 83.7 59.3 121 139 230 170 231 181
Capex / Sales 5.78% 4% 7.17% 7.17% 9.9% 6.22% 7.77% 5.72%
Announcement Date 20-02-26 21-02-24 22-02-24 23-02-22 24-02-21 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
297.1 USD
Average target price
295.9 USD
Spread / Average Target
-0.37%
Consensus
  1. Stock Market
  2. Equities
  3. UTHR Stock
  4. Financials United Therapeutics Corporation